Overview of Peptides Are Everywhere. Businesses Are Cashing In.
This episode of The Journal examines the booming peptide wellness market and why it’s suddenly attracting major attention from consumers, regulators, and businesses. Peptides—chains of amino acids that naturally occur in the body and can influence functions like metabolism, recovery, and sleep—have become a social media wellness obsession, promoted for benefits like fat loss, muscle growth, skin health, hair growth, energy, and injury recovery. But most of the popular products discussed online are experimental, often unapproved, and widely sold through gray-market channels. With the FDA under pressure to reconsider restrictions, telehealth and wellness companies are racing to position themselves for a potential peptide gold rush.
What Peptides Are and Why They’re Trending
Peptides in the wellness conversation
- Peptides are naturally occurring in the body; examples include insulin and endorphins.
- The social media craze centers on manufactured peptides marketed for specific outcomes:
- clearer skin
- bigger muscles
- faster recovery
- healthier hair
- more energy
- tanning / melanin boosting
- Popular names mentioned include:
- BPC-157 and TB-500 for healing/recovery
- MOTS-c for energy
- MT2 (“the tanning peptide”)
Why interest exploded
- The popularity of GLP-1 drugs like Ozempic made peptides a mainstream concept.
- Even though GLP-1s are FDA-approved drugs backed by clinical trials, their success helped open the door to broader public curiosity about peptide-based solutions.
- Influencers, celebrities, and biohacking communities have fueled the sense that peptides are “miracle substances.”
The Risks and Regulatory Concerns
Major safety concerns
- Most of the peptides being discussed are experimental and not FDA-approved.
- Much of the evidence is anecdotal, not based on rigorous human trials.
- Doctors cited concerns about:
- unintended tissue growth
- polyps or cancerous cell growth
- unknown interactions when people “stack” multiple peptides
- contamination or mislabeling in online products
How people are getting them
- Many people buy peptides online from sellers, often abroad.
- Some products are sold with disclaimers like “for research use only” or “not for human consumption” as a workaround.
- Users may mix powdered peptides at home with bacteriostatic water and inject them themselves, often without medical supervision.
The FDA’s Changing Position
Under the Biden administration
- The FDA flagged safety concerns and limited the compounding of many peptides.
- In 2023, more than a dozen peptides were placed on a do-not-compound list, restricting U.S. compounding pharmacies from making them.
Under RFK Jr. and the Trump administration
- Health Secretary Robert F. Kennedy Jr. has been openly supportive of peptides and has said he’s used them himself.
- He has vowed to “end the war on peptides,” signaling a more permissive regulatory direction.
- A recent FDA advisory committee meeting recommended allowing compounding pharmacies to make six of seven peptides under review.
Important caveat
- Even if restrictions are loosened, these peptides would still not be FDA-approved drugs.
- That means they would not have the same evidence base or safety standards as approved medications.
- Public health advocates warned that patients may wrongly interpret the decision as a full FDA endorsement.
How Businesses Are Positioning Themselves
Telehealth and wellness companies see opportunity
Major players are already preparing for a broader peptide market:
- Hims & Hers
- acquired a peptide compounding facility in Menlo Park
- Noom
- acquired TaylorMade Compounding, which operates in 46 states
- Both companies testified in favor of peptides at the FDA hearing
Market potential
- Analysts estimate the opportunity could be worth more than $2 billion in telehealth alone.
Smaller companies are moving faster
- Some smaller wellness platforms are already offering peptides or peptide-related services.
- Examples mentioned:
- Mino, a platform for doctors and med spas
- Protocol, a telehealth company marketing itself as sourcing from state-regulated pharmacies
- These companies are betting that regulatory change is coming and want to establish themselves early.
Why This Matters Beyond Peptides
A broader shift in wellness culture
- The episode suggests a larger trend: people increasingly want to take control of their own health and longevity, even if that means using unapproved substances.
- Many consumers appear to trust:
- anecdotal stories
- influencer testimonials
- social media trends
more than they trust formal medical and regulatory institutions.
Core tension
- The peptide boom sits at the intersection of:
- consumer demand
- weak or incomplete evidence
- regulatory uncertainty
- commercial opportunism
- That makes it both a business opportunity and a public health concern.
Key Takeaways
- Peptides have moved from niche biohacking circles into mainstream wellness culture.
- Popularity has been amplified by social media and the success of GLP-1 drugs.
- Most of the products being sold are not FDA-approved and carry uncertain risks.
- The FDA may soon loosen compounding restrictions, but the timeline is still months away and the outcome is not final.
- Large telehealth companies and smaller wellness startups are already positioning themselves to profit from a more peptide-friendly market.
Bottom Line
The episode portrays peptides as the next big battleground in wellness: a fast-growing market driven by hype, personal experimentation, and weak oversight, with businesses racing to capitalize before the rules are fully settled.